HK1204553A1 - Extended-release formulation for reducing the frequency of urination and method of use thereof - Google Patents

Extended-release formulation for reducing the frequency of urination and method of use thereof

Info

Publication number
HK1204553A1
HK1204553A1 HK15105034.0A HK15105034A HK1204553A1 HK 1204553 A1 HK1204553 A1 HK 1204553A1 HK 15105034 A HK15105034 A HK 15105034A HK 1204553 A1 HK1204553 A1 HK 1204553A1
Authority
HK
Hong Kong
Prior art keywords
urination
extended
frequency
reducing
release formulation
Prior art date
Application number
HK15105034.0A
Other languages
English (en)
Chinese (zh)
Inventor
大衛‧
‧迪爾
伊麗婭‧
‧沃爾夫松
Original Assignee
Wellesley Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/424,000 external-priority patent/US8236857B2/en
Priority claimed from US13/487,348 external-priority patent/US20120244221A1/en
Application filed by Wellesley Pharmaceuticals Llc filed Critical Wellesley Pharmaceuticals Llc
Publication of HK1204553A1 publication Critical patent/HK1204553A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
HK15105034.0A 2012-03-19 2015-05-27 Extended-release formulation for reducing the frequency of urination and method of use thereof HK1204553A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/424,000 US8236857B2 (en) 2010-07-08 2012-03-19 Extended-release formulation for reducing the frequency of urination and method of use thereof
US13/487,348 US20120244221A1 (en) 2010-07-08 2012-06-04 Extended-release formulation for reducing the frequency of urination and method of use thereof
PCT/US2013/031617 WO2013142274A1 (en) 2012-03-19 2013-03-14 Extended-release formulation for reducing the frequency of urination and method of use thereof

Publications (1)

Publication Number Publication Date
HK1204553A1 true HK1204553A1 (en) 2015-11-27

Family

ID=49223209

Family Applications (3)

Application Number Title Priority Date Filing Date
HK15105034.0A HK1204553A1 (en) 2012-03-19 2015-05-27 Extended-release formulation for reducing the frequency of urination and method of use thereof
HK18110965.0A HK1251469A1 (zh) 2012-03-19 2015-05-27 用於緩解尿頻的延長釋放製劑及其使用方法
HK18103371.3A HK1243921A1 (zh) 2012-03-19 2018-03-10 用於緩解尿頻的延長釋放製劑及其使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
HK18110965.0A HK1251469A1 (zh) 2012-03-19 2015-05-27 用於緩解尿頻的延長釋放製劑及其使用方法
HK18103371.3A HK1243921A1 (zh) 2012-03-19 2018-03-10 用於緩解尿頻的延長釋放製劑及其使用方法

Country Status (15)

Country Link
EP (2) EP2827852A4 (xx)
JP (5) JP2015510928A (xx)
KR (4) KR20140134333A (xx)
CN (4) CN107157991A (xx)
AU (4) AU2013235518B2 (xx)
BR (2) BR112014020271A8 (xx)
CA (2) CA2866853A1 (xx)
HK (3) HK1204553A1 (xx)
MX (3) MX2014011128A (xx)
MY (2) MY174090A (xx)
NZ (6) NZ630471A (xx)
RU (3) RU2669565C2 (xx)
SG (2) SG11201500408VA (xx)
WO (2) WO2013142197A1 (xx)
ZA (2) ZA201405862B (xx)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10596127B2 (en) 2013-03-14 2020-03-24 Wellesley Pharmaceuticals, Llc Composition for reducing the frequency of urination, method of making and use thereof
AU2014293141A1 (en) 2013-07-23 2016-02-18 Serenity Pharmaceuticals Llc Methods and compositions comprising desmopressin in combination with a beta-3 adrenergic receptor agonist
WO2015187183A1 (en) * 2014-06-06 2015-12-10 Wellesley Pharmaceuticals, Llc Pharmaceutical formulation for reducing frequency of urination and method of use thereof
KR101809908B1 (ko) * 2014-07-21 2018-01-25 주식회사 종근당 5-알파환원효소억제제를 포함하는 조성물
CA2967390A1 (en) * 2014-11-20 2016-05-26 Allergan, Inc. Methods and compositions comprising desmopressin in combination with an alpha-adrenergic receptor antagonist
CN108430465A (zh) * 2015-09-30 2018-08-21 韦尔斯利医药有限公司 用于缓解尿频的组合物、其制造方法和用途
SG11201805530RA (en) * 2015-09-30 2018-07-30 Wellesley Pharmaceuticals Llc Composition for reducing the frequency of urination, method of making and use thereof
CN105238124B (zh) * 2015-11-16 2018-02-09 太仓东能环保设备有限公司 一种抗菌腻子粉
JP6294924B2 (ja) 2016-09-05 2018-03-14 株式会社Ｓｕｂａｒｕ 車両の走行制御装置

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303144B1 (en) * 1998-02-10 2001-10-16 Welfide Corporation Preparations with controlled release
US20020102309A1 (en) * 1999-09-14 2002-08-01 Jane C. I. Hirsh Controlled release formulation for administration of an anti-inflammatory naphthalene derivative
DE10116978A1 (de) * 2001-04-05 2002-10-10 Merck Patent Gmbh Kappa-Opiatagonisten für die Behandlung von Erkrankungen der Blase
US20030091630A1 (en) * 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
JP2005526040A (ja) * 2002-02-19 2005-09-02 ファルマシア・コーポレーション 失禁の治療のためのシクロオキシゲナーゼ阻害剤及び抗ムスカリン剤の使用
WO2003103659A1 (ja) * 2002-06-07 2003-12-18 山之内製薬株式会社 過活動膀胱治療剤
US20040054008A1 (en) * 2002-09-13 2004-03-18 Tohru Araki Medicament for treatment of nocturia
US20040198822A1 (en) * 2003-03-21 2004-10-07 Dynogen Pharmacueticals, Inc. Methods for treating lower urinary tract disorders using alpha2delta subunit calcium channel modulators with smooth muscle modulators
WO2004093864A1 (en) * 2003-03-21 2004-11-04 Mcneil-Ppc, Inc. Non-steroidal anti-inflammatory drug dosing regimen
EP1627876A1 (en) * 2004-08-20 2006-02-22 Ferring B.V. Heterocyclic condensed compounds useful as antidiuretic agents
JP5173190B2 (ja) * 2004-08-25 2013-03-27 武田薬品工業株式会社 腹圧性尿失禁の予防・治療剤及びそのスクリーニング方法
JP2009501700A (ja) * 2005-06-17 2009-01-22 ダイナミス・セラピユーテイクス・インコーポレーテツド 炎症状態の治療
US20080085314A1 (en) * 2005-07-29 2008-04-10 Shalaby Shalaby W Solid oral formulations for combination therapy
WO2007027675A1 (en) * 2005-09-02 2007-03-08 Theravida, Inc Therapy for the treatment of disease
WO2010138441A1 (en) * 2009-05-28 2010-12-02 Aptapharma, Inc. Multilayer oral tablets containing a non-steroidal anti-inflammatory drug and/or acetaminophen
GB201003731D0 (en) * 2010-03-05 2010-04-21 Univ Strathclyde Immediate/delayed drug delivery
US20120244221A1 (en) * 2010-07-08 2012-09-27 Wellesley Pharmaceuticals, Llc Extended-release formulation for reducing the frequency of urination and method of use thereof
US20120010294A1 (en) * 2010-07-08 2012-01-12 Dill David A Compositions and methods for the inhibition of muscle contraction

Also Published As

Publication number Publication date
HK1251469A1 (zh) 2019-02-01
HK1243921A1 (zh) 2018-07-27
RU2014142066A (ru) 2016-05-10
AU2013235518A1 (en) 2014-09-25
RU2599017C2 (ru) 2016-10-10
JP2015510936A (ja) 2015-04-13
BR112014020113A8 (pt) 2017-07-11
MX2014011128A (es) 2015-08-10
KR20140134284A (ko) 2014-11-21
NZ718163A (en) 2017-09-29
JP2016172752A (ja) 2016-09-29
AU2017203139A1 (en) 2017-06-01
AU2017203246A1 (en) 2017-06-08
EP2827852A1 (en) 2015-01-28
AU2013235518B2 (en) 2017-03-02
MX2019008817A (es) 2019-09-26
SG11201500408VA (en) 2015-03-30
NZ630471A (en) 2016-04-29
JP2018024693A (ja) 2018-02-15
BR112014020271A8 (pt) 2017-07-11
ZA201406146B (en) 2016-08-31
RU2016133305A3 (xx) 2018-12-10
CN107157991A (zh) 2017-09-15
CN104321056A (zh) 2015-01-28
WO2013142197A1 (en) 2013-09-26
CN107789626A (zh) 2018-03-13
NZ714288A (en) 2016-12-23
KR20190003840A (ko) 2019-01-09
CA2866853A1 (en) 2013-07-26
JP2018138602A (ja) 2018-09-06
WO2013142274A1 (en) 2013-09-26
AU2017203246B2 (en) 2018-10-18
AU2017203139B2 (en) 2018-07-19
NZ628079A (en) 2016-05-27
NZ712594A (en) 2016-09-30
AU2013235507B2 (en) 2017-03-23
JP2015510928A (ja) 2015-04-13
KR20170015537A (ko) 2017-02-08
BR112014020113A2 (xx) 2017-06-20
MY174090A (en) 2020-03-09
CA2866755A1 (en) 2013-09-26
RU2669565C2 (ru) 2018-10-12
SG11201500409SA (en) 2015-03-30
NZ714662A (en) 2016-08-26
CN104302284A (zh) 2015-01-21
RU2016133305A (ru) 2018-12-10
EP2827852A4 (en) 2016-03-02
RU2014142025A (ru) 2016-05-10
KR20140134333A (ko) 2014-11-21
AU2013235518A2 (en) 2014-10-09
MX2014011129A (es) 2015-08-10
MY175764A (en) 2020-07-08
ZA201405862B (en) 2016-08-31
BR112014020271A2 (xx) 2017-06-20
AU2013235507A1 (en) 2014-08-21
EP2827851A4 (en) 2015-10-14
EP2827851A1 (en) 2015-01-28

Similar Documents

Publication Publication Date Title
IL274404A (en) Body expandable device and method for use
IL261768B (en) Devices and methods for tissue treatment
HK1243921A1 (zh) 用於緩解尿頻的延長釋放製劑及其使用方法
IL232715A0 (en) The delayed-release composition for reducing the frequency of urination and a method for using it
HK1200690A1 (en) Expandable body device and method of use
ZA201403762B (en) Delayed-release formulation for reducing the frequency of urination and method of use thereof
EP2709562A4 (en) FABRIC BACKUP DEVICES AND USE METHOD THEREFOR
RS59200B1 (sr) Derivati c4-monometil triterpenoida i postupci za njihovu upotrebu
EP2613735A4 (en) DEVICES AND METHODS FOR THE TREATMENT OF VASCULAR ABNORMALITIES
EP2825242A4 (en) DEVICES AND METHOD FOR THE TREATMENT OF VASCULAR DEFECTS
EP2790709A4 (en) HEMOSTATIC ACTIVE SUBSTANCES AND METHOD OF USE THEREOF
EP2938289A4 (en) DEVICES AND METHODS FOR TREATING VASCULAR DEFECTS
IL261232A (en) A pharmaceutical formulation for reducing urinary frequency and a method for its use
HK1249438A1 (zh) 用於緩解尿頻的緩釋製劑及其使用方法
HK1203395A1 (en) Implantable devices and methods for the evaluation of active agent
ZA201408055B (en) Compositions and methods for the treatment of local pain
HK1248549A1 (zh) 用於緩解尿頻的延長釋放製劑及其使用方法
HK1203159A1 (en) Prophylactic agent and or therapeutic agent for stress urinary incontinence
AP3759A (en) Method for preparing phenyloxymethyl-nitro-imidazole derivatives and use of the same